{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T20:49:04Z","timestamp":1771879744982,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2004,10,26]],"date-time":"2004-10-26T00:00:00Z","timestamp":1098748800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2005,4]]},"DOI":"10.1007\/s00280-004-0911-1","type":"journal-article","created":{"date-parts":[[2004,10,25]],"date-time":"2004-10-25T10:29:37Z","timestamp":1098700177000},"page":"323-332","source":"Crossref","is-referenced-by-count":19,"title":["A possible mechanism for the long-lasting antitumor effect of the macromolecular conjugate DE-310: mediation by cellular uptake and drug release of its active camptothecin analog DX-8951"],"prefix":"10.1007","volume":"55","author":[{"given":"Yusuke","family":"Ochi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshinobu","family":"Shiose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Kuga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiji","family":"Kumazawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2004,10,26]]},"reference":[{"key":"CR1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0079-6468(08)70105-X","volume":"34","author":"Y Kawato","year":"1997","unstructured":"Kawato Y, Terasawa H (1997) Recent advances in the medical chemistry and pharmacology of camptothecin. Prog Med Chem 34:69?109","journal-title":"Prog Med Chem"},{"key":"CR2","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1111\/j.1349-7006.1995.tb02468.x","volume":"86","author":"I Mitsui","year":"1995","unstructured":"Mitsui I, Kumazawa E, Hirota Y, Aonuma M, Sugimori M, Ohsuki S, Uoto K, Ejima A, Terasawa H, Sato K (1995) A new water-soluble camptothecin derivative, DX-8951f, exhibits potent antitumor activity against human tumors in vitro and in vivo. Jpn J Cancer Res 86:776?782","journal-title":"Jpn J Cancer Res"},{"key":"CR3","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1002\/(SICI)1097-0215(19970807)72:4<680::AID-IJC21>3.0.CO;2-E","volume":"72","author":"N Joto","year":"1997","unstructured":"Joto N, Ishii M, Minami M, Kuga H, Mitsui I, Tohgo A (1997) DX-8951f, a water-soluble camptothecin analog, exhibits potent antitumor activity against a human lung cancer cell line and its SN-38-resistant variant. Int J Cancer 72:680?686","journal-title":"Int J Cancer"},{"key":"CR4","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/j.1349-7006.1997.tb00448.x","volume":"88","author":"S Takiguchi","year":"1997","unstructured":"Takiguchi S, Kumazawa E, Shimazoe T, Tohgo A, Kono A (1997) Antitumor effect of DX-8951, a novel camptothecin analog, on human pancreatic tumor cells and their CPT-11-resistant variants cultured in vitro and xenografted into nude mice. Jpn J Cancer Res 88:760?769","journal-title":"Jpn J Cancer Res"},{"key":"CR5","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1007\/s002800050807","volume":"42","author":"E Kumazawa","year":"1998","unstructured":"Kumazawa E, Jimbo T, Ochi Y, Tohgo A (1998) Potent and broad antitumor effects of DX-8951f, a water-soluble camptothecin derivative, against various human tumors xenografted in nude mice. Cancer Chemother Pharmacol 42:210?220","journal-title":"Cancer Chemother Pharmacol"},{"key":"CR6","first-page":"6387","volume":"46","author":"Y Matsumura","year":"1986","unstructured":"Matsumura Y, Maeda H (1986) A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 46:6387?6392","journal-title":"Cancer Res"},{"key":"CR7","first-page":"193","volume":"6","author":"H Maeda","year":"1989","unstructured":"Maeda H, Matsumura Y (1989) Tumoritropic and lymphotropic principles of macromolecular drugs. Crit Rev Ther Drug Carrier Syst 6:193?210","journal-title":"Crit Rev Ther Drug Carrier Syst"},{"key":"CR8","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0168-3659(99)00248-5","volume":"65","author":"H Maeda","year":"2000","unstructured":"Maeda H, Wu J, Sawa T, Matsumura Y, Hori K (2000) Tumor vascular permeability and EPR effect in macromolecular therapeutics: a review. J Control Release 65:271?284","journal-title":"J Control Release"},{"key":"CR9","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0065-2571(00)00013-3","volume":"41","author":"H Maeda","year":"2001","unstructured":"Maeda H (2001) The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul 41:189?207","journal-title":"Adv Enzyme Regul"},{"key":"CR10","first-page":"361","volume":"5","author":"IJ Goldstein","year":"1965","unstructured":"Goldstein IJ, Hay GW, Lewis A, Smith F (1965) Controlled degradation of polysaccharides by periodate oxidation, reduction, and hydrolysis. Methods Carbohydr Chem 5:361?370","journal-title":"Methods Carbohydr Chem"},{"key":"CR11","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/0-306-47932-X_9","volume":"519","author":"K Inoue","year":"2003","unstructured":"Inoue K, Kumazawa E, Kuga H, Susaki H, Masubuchi N, Kajimura T (2003) CM-dextran-polyalcohol-camptothecin conjugate; DE-310 with a novel carrier system and its preclinical data. Adv Exp Med Biol 519:145?153","journal-title":"Adv Exp Med Biol"},{"key":"CR12","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1093\/jnci\/89.17.1260","volume":"89","author":"AF Chambers","year":"1997","unstructured":"Chambers AF, Matrisian LM (1997) Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 89:1260?1270","journal-title":"J Natl Cancer Inst"},{"key":"CR13","first-page":"215","volume":"1477","author":"J Mai","year":"2000","unstructured":"Mai J, Waisman DM, Sloane BF (2000) Cell surface complex of cathepsin B\/annexin II tetramer in malignant progression. Biochem Biophys Acta 1477:215?230","journal-title":"Biochem Biophys Acta"},{"key":"CR14","first-page":"262","volume":"7","author":"R Duncan","year":"1997","unstructured":"Duncan R (1997) Polymer therapeutics for tumor specific delivery. Chem Ind 7:262?264","journal-title":"Chem Ind"},{"key":"CR15","first-page":"1663","volume":"32","author":"GB Feldman","year":"1972","unstructured":"Feldman GB, Knapp RC, Order SE, Hellman S (1972) The role of lymphatic obstruction in the formation of ascites in a murine ovarian carcinoma. Cancer Res 32:1663?1666","journal-title":"Cancer Res"},{"key":"CR16","first-page":"2631","volume":"53","author":"JA Nagy","year":"1993","unstructured":"Nagy JA, Herzberg KT, Dvorak JM, Dvorak HF (1993) Pathogenesis of malignant ascites formation: initiating events that lead to fluid accumulation. Cancer Res 53:2631?2643","journal-title":"Cancer Res"},{"key":"CR17","first-page":"325","volume":"35","author":"GB Feldman","year":"1975","unstructured":"Feldman GB (1975) Lymphatic obstruction in carcinomatous ascites. Cancer Res 35:325?332","journal-title":"Cancer Res"},{"key":"CR18","first-page":"5629","volume":"46","author":"DR Senger","year":"1986","unstructured":"Senger DR, Peruzzi CA, Feder J, Dvorak HF (1986) A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines. Cancer Res 46:5629?5632","journal-title":"Cancer Res"},{"key":"CR19","first-page":"1774","volume":"50","author":"DR Senger","year":"1990","unstructured":"Senger DR, Connoly DT, Van De Water L, Dvorak HF (1990) Purification and NH2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor. Cancer Res 50:1774?1778","journal-title":"Cancer Res"},{"key":"CR20","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S1567-5769(02)00271-0","volume":"3","author":"H Maeda","year":"2003","unstructured":"Maeda H, Fang J, Inutsuka T, Kitamoto Y (2003) Vascular permeability enhancement in solid tumor: various factors, mechanisms involved and its implications. Int Immunopharmacol 3:319?328","journal-title":"Int Immunopharmacol"},{"key":"CR21","first-page":"2988","volume":"60","author":"S Okuno","year":"2000","unstructured":"Okuno S, Harada M, Yano T, Yano S, Kiuchi S, Tsuda N, Sakamura Y, Imai J, Kawaguchi T, Tsujihara K (2000) Complete regression of xenografted human carcinomas by camptothecin analogue-carboxymethyl dextran conjugate (T-0128). Cancer Res 60:2988?2995","journal-title":"Cancer Res"},{"key":"CR22","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S0168-3659(00)00320-5","volume":"69","author":"M Harada","year":"2000","unstructured":"Harada M, Imai J, Okuno S, Suzuki T (2000) Macrophage-mediated activation of camptothecin analogue T-2513-carboxymethyl dextran conjugate (T-0128): possible cellular mechanism for antitumor activity. J Control Release 69:389?397","journal-title":"J Control Release"},{"key":"CR23","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/S0168-3659(00)00321-7","volume":"69","author":"M Harada","year":"2000","unstructured":"Harada M, Sakakibara H, Yano T, Suzuki T, Okuno S (2000) Determinants for the drug release from T-0128, camptothecin analogue-carboxymethyl dextran conjugate. J Control Release 69:399?412","journal-title":"J Control Release"},{"key":"CR24","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0168-3659(00)00372-2","volume":"71","author":"M Harada","year":"2001","unstructured":"Harada M, Murata J, Sakamura Y, Sakakibara H, Okuno S, Suzuki T (2001) Carrier and dose effects on the pharmacokinetics of T-0128, a camptothecin analogue-carboxymethyl dextran conjugate, in non-tumor- and tumor-bearing rats. J Control Release 71:71?86","journal-title":"J Control Release"},{"key":"CR25","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/jemt.1060180107","volume":"18","author":"GJ Smith","year":"1991","unstructured":"Smith GJ, Bagnell CR, Bakewell WE, Black KA, Bouldin TW, Earnhardt TS, Hook GER, Pryzwansky KB (1991) Application of confocal scanning microscopy in experimental pathology. J Electron Microsc Tech 18:38?49","journal-title":"J Electron Microsc Tech"},{"key":"CR26","first-page":"331","volume":"22","author":"H Oyama","year":"1992","unstructured":"Oyama H, Nagane M, Shibui S, Nomura K, Mukai K (1992) Intracellular distribution of CPT-11-resistant cells with confocal laser scanning microscopy. Jpn J Clin Oncol 22:331?334","journal-title":"Jpn J Clin Oncol"},{"key":"CR27","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/eji.1830090410","volume":"9","author":"T Springer","year":"1979","unstructured":"Springer T, Galfre ?, Secher DS, Milstein C (1979) Mac 1: a macrophage differentiation antigen identified by monoclonal antibody. Eur J Immunol 9:301?306","journal-title":"Eur J Immunol"},{"key":"CR28","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/289409a0","volume":"289","author":"RS Denise","year":"1981","unstructured":"Denise RS, Frank MG (1981) Phagocytosis requires repeated triggering of macrophage phagocytic receptors during particle ingestion. Nature 289:409?411","journal-title":"Nature"},{"key":"CR29","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/path.1711720302","volume":"172","author":"C O?sllivan","year":"1994","unstructured":"O?sllivan C, Lewis CE (1994) Tumor-associated leucocytes: friends or foes in breast carcinoma. J Pathol 172:229?235","journal-title":"J Pathol"},{"key":"CR30","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0169-409X(96)00400-0","volume":"21","author":"H Soyez","year":"1996","unstructured":"Soyez H, Schacht E, Vanderkerken S (1996) The crucial role of spacer groups in macromolecular prodrug design. Adv Drug Deliv Rev 21:81?106","journal-title":"Adv Drug Deliv Rev"},{"key":"CR31","series-title":"Protein profile 2","first-page":"1587","volume-title":"Proteinases 1: lysosomal cysteine proteinases","author":"H Kirschke","year":"1995","unstructured":"Kirschke H, Barrett AJ, Rawlings ND (1995) Proteinases 1: lysosomal cysteine proteinases. Protein profile 2. Academic Press, London, pp 1587?1643"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-004-0911-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-004-0911-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-004-0911-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T10:06:09Z","timestamp":1559037969000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-004-0911-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,10,26]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2005,4]]}},"alternative-id":["911"],"URL":"https:\/\/doi.org\/10.1007\/s00280-004-0911-1","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,10,26]]}}}